Advertisement
Markets

Groundhog Day Meltdown Casts Shadow Over Stock Market

Dow plunges more than 600 points on Friday after January jobs report causes jitters, and Exxon earnings and Apple earnings disappoint.

Call it a coincidence, but Punxsutawney Phil's prediction of six more weeks of winter seemingly had a chilling effect on the stock market.

What Happened in the Stock Market Today?

While Main Street celebrated a January employment report that showed better-than-expected job growth and the fastest pace of wage growth in eight years, Wall Street took the news much differently. Concerns over the potential impact of a tightening labor market on Corporate America, not to mention a couple of faceplants by large Dow components, sent the industrial average down 2.5% to 25,520 on Friday, Feb. 2. All told, the Dow has lost 4.1% over the past five sessions -- including the Groundhog Day decline of 666 points -- marking its worst single-week performance since January 2016.

Advertisement - Article continues below

The wage-growth worry on Wall Street is twofold: Fatter paychecks for employees could eventually cut into company profits, and rising wages could be signaling a coming pickup in inflation. The latter, in theory, could trigger quicker rate hikes by the Federal Reserve -- a fear that's showing up in the bond market, with the 10-year Treasury yield hitting multiyear highs above 2.8%. Also hampering the Dow were Exxon Mobil (XOM, -5.3%), which missed earnings expectations, and Apple (AAPL, -4.4%), which beat profit estimates but earned analyst downgrades because quarterly iPhone sales came up short.

Advertisement
Advertisement - Article continues below

This week was ugly -- adorable woodchuck aside -- but it's far from time to hit the panic button. Instead, it may just be a reminder to be more critical about strategy and timing. For instance, a number of high-yield dividend stocks have quietly been dipping for several months, and already are reaching bargain prices. But even the market's most stable of blue chips have lost a little skin this week, and could shed more in a steeper broad-market downturn. Opportunistic investors should keep on the watch for the chance to buy these quality names on the cheap.

Advertisement

Most Popular

12 Tax Deadlines for July 15 (It's Not Just the Due Date for Your Tax Return)
tax deadline

12 Tax Deadlines for July 15 (It's Not Just the Due Date for Your Tax Return)

Between due dates for IRA or HSA contributions, paying estimated taxes and other deadlines, there's more to do by July 15 than just filing your federa…
July 10, 2020
Know Why Your Credit Score Changes: 9 Money Moves to Consider
credit & debt

Know Why Your Credit Score Changes: 9 Money Moves to Consider

Your credit score is a key indicator of your financial well-being and of the risk you pose to lenders. How good is yours?
July 10, 2020
65 Best Dividend Stocks You Can Count On
stocks

65 Best Dividend Stocks You Can Count On

These 65 Dividend Aristocrats are an elite group of dividend stocks that have reliably increased their annual payouts every year for at least a quarte…
July 8, 2020

Recommended

Closing Bell 7/13/20: This Is Your Market on (Coronavirus) Drugs
Markets

Closing Bell 7/13/20: This Is Your Market on (Coronavirus) Drugs

A rapid rally to start the week, sparked by encouraging vaccine news from Pfizer and BioNTech, collapsed in the afternoon.
July 13, 2020
91 Top Dividend Stocks From Around the World
stocks

91 Top Dividend Stocks From Around the World

These 91 Dividend Aristocrats, from the U.S., Canada and Europe, are among the world's top dividend stocks for payout longevity and safety.
July 13, 2020
3 Municipal Bond Funds for Rich, Tax-Friendly Yields
Investing for Income

3 Municipal Bond Funds for Rich, Tax-Friendly Yields

Municipal bond funds allow you to enjoy the benefits of tax-exempt income. By investing in CEFs, you can sweeten the pot even further.
July 13, 2020
Closing Bell 7/10/20: Gilead Gives Stocks a Booster Shot
Markets

Closing Bell 7/10/20: Gilead Gives Stocks a Booster Shot

Stocks rallied out of negative territory Friday after Gilead announced that remdesivir helped reduce COVID-19 mortality risk in a clinical trial.
July 10, 2020